Abstract: Caustic-free detergent compositions are provided. Detergent compositions including an aminocarboxylate, water conditioning agent, non-caustic source of alkalinity and water beneficially do not require the use of additional surfactants and/or polymers to provide suitable detergency and prevent scale build-up on treated surfaces. The detergent compositions are used with a sanitizer to employ the caustic-free detergent compositions are particularly suitable for use as low temperature ware wash detergents that beneficially reduce scale build-up. Methods of employing the caustic-free detergent compositions are also provided.

Abstract: A cleaning product having a spray dispenser and a cleaning composition suitable for spraying and foaming, the composition housed in the spray dispenser wherein the composition contains: i) 2 to 15% by weight of a surfactant system comprising an alkyl ethoxylated sulfate anionic surfactant and a specific co-surfactant; and ii) a specific glycol ether solvent.

Abstract: An effervescent detergent tablet comprising calcium carbonate, sodium laureth sulfate, citric acid, tartaric acid, sodium bicarbonate, fragrance, Stepantex VT 90 (Methyl bis[ethyl (tallowate)]-2-hydroxyethyl ammonium methyl sulfate), polyhexamethylene biguanide (PHMB), stearic acid, silicon dioxide, enzymes mix, Long Brite (Disodium Distyrylbiphenyl Disulfonate) Magnesium Stearate, Kollidon CL, Chlorhexidine Hydrochloride and calcium carbonate and sodium disilicate mix.

Abstract: Water-soluble unit dose article containing solid laundry detergent composition and water-soluble film.

Abstract: Water-soluble unit dose article containing solid laundry detergent composition and water-soluble film.

Abstract: Water-soluble unit dose article containing solid laundry detergent composition and water-soluble film.

Abstract: A water-soluble pouch suitable for use in machine dishwashing and which comprises a plurality of compartments in generally superposed or superposable relationship, each containing one or more detergent active or auxiliary components, and wherein the pouch has a volume of from about 5 to about 70 ml and a longitudinal/transverse aspect ratio in the range from about 2:1 to about 1:8, preferably from about 1:1 to about 1:4. The water-soluble pouch allows for optimum delivery of dishwashing detergent. A process for the manufacture of multi-compartment pouches and a pack to contain the pouches are also disclosed.

Abstract: A system and method of controlling a concentration of one or more gases dissolved in a beverage is disclosed. The system includes a saturation tank having a gas head space, a brite tank, and a beverage supply system to pass the beverage between the saturation tank and the brite tank. A beverage supersaturated with the gas from the head space is formed in the saturation tank. The supersaturated beverage is passed from the saturation tank to the brite tank. Once the amount of gas added to the beverage exceeds saturation, some of the gas escapes from solution from the beverage and the pressure in the brite tank increases. Once the pressure within the brite tank reaches a pre-defined pressure, a pump supplying the beverage to the saturation tank is shut-off and the inlet and outlet valves of the brite tank are closed.

Abstract: A brewing system may include a first container defining an interior space for brewing a liquid. The first container may include a plurality of legs extending from a lower portion of the first container, and a lid removably connectable to an upper opening of the first container. The first container may be stackable on an identical second container such that the plurality of legs of the first container are seated in one or more slots on opposing sides of a lid of the identical second container.

Abstract: Systems and methods are disclosed herein for use in transducing, activating, and otherwise treating cells. Cells are introduced into an inner layer of a multi-layered stack that defines at least one flow chamber and a plurality of cell entrainment regions. Vertical flow through the stack entrains the cells in the cell entrainment regions along with genetic information introduction agents or other additives, before the cells are washed using a reverse vertical flow and are collected from the device.

Abstract: In one embodiment, a disposable bioreactor including a headplate and a stirrer. The headplate has at least one inlet port aperture and one outlet port aperture formed therein and is adapted to couple sealingly with a bag capable of receiving a culture medium. The stirrer is coupled to and extends from the headplate and is adapted to stir the culture medium when the headplate is coupled to the bag. The bioreactor is adapted to fit within the upper opening of the stand of an existing conventional glass bioreactor, so that the bag is suspended within the vessel.

Abstract: A laboratory system has a plurality of bottom opening sample transport pods for carrying one or more cassettes with cell culture vessels therein may have an aseptic interior environment and may cooperate with cell culture growing/processing stations having load ports allowing transfer of the cassettes with cell culture vessels into the stations while maintaining the aseptic integrity of the interior of the pods and the cassette and cell culture vessels. Internal environmental monitoring and control, purging, and tracking as well as automated robotic operation may be provided.

Abstract: A three-dimensional cell culture support and preparation method thereof. The preparation method comprises the following steps: designing, according to a shape of a cell culture device, a shape of the three-dimensional cell culture support; printing once by a 3D printer to form the three-dimensional cell culture support; performing a surface treatment, by a surface treating agent, on the three-dimensional cell culture support manufactured by 3D printing to obtain a resultant three-dimensional cell culture support. By adopting a three-dimensional printing technology to manufacture a three-dimensional fibrous cell culture support having a three-dimensional fibrous network structure, raw materials and a manufacturing time can be saved, reducing production costs, increasing production efficiency, decreasing power consumption, preventing a flaw in the conventional manufacturing technique, and facilitating large-scale intelligent manufacturing.

Abstract: The present invention relates to membranes comprising at least two types of porosity: —a porosity of small size but of high density, allowing for the support and nutrition of culture cells in such a way as to obtain a reconstructed tissue model, and —a porosity of large size but of low density, allowing for the circulation of some cell types and the passage of cytoplasmic extensions from one compartment to another.

Abstract: The present disclosure relates to a nanofiber structure for cell culture, a method for manufacturing the structure, and a cell analysis device including the nanofiber structure for cell culture. The structure includes a cell culture layer made of nanofibers; and a spacer protruding upward from a surface of the cell culture layer, wherein the spacer divides a region on the cell culture layer into at least two culturing regions, wherein the spacer is made of the same nanofibers as the cell culture layer and thus has a cell migration channel defined therein.

Abstract: A rotating bioreactor. A bioreactor base has a cover support section positioned within the base. Air holes extend through the base and connect to the cover support section. An air permeable membrane is positioned on top of the cover support section and covers the air holes. A base cover has a chamber tube extending through the base cover. The base cover is inserted onto the base and is supported by the cover support section. A sealing mechanism is positioned between the base cover and membrane. A septum is attached to the base cover. A cell containment chamber is formed within the rotating bioreactor and is bordered by the membrane, the sealing mechanism, the chamber tube and the septum. The cell containment chamber is air permeable but water and fluid impermeable.

Abstract: A liquid delivery device includes a first and second container for a first and second liquid; a third container for receiving a first and second liquid; a fourth container into which a first and second liquid are discharged; a fifth container for a third liquid; a first liquid delivery tube for delivering a first liquid; a second liquid delivery tube for delivering a second liquid; a third liquid delivery tube connected to the first and second liquid delivery tube; a first liquid delivery pump on the third liquid delivery tube; a fourth liquid delivery tube for discharging a first liquid contained in the third container and delivering a third liquid to the third container; a fifth liquid delivery tube connected to the fourth liquid delivery tube; a sixth liquid delivery tube connected to the fourth liquid delivery tube; and a second liquid delivery pump on the fourth liquid delivery tube.

Abstract: Disclosed herein is an improved automatic sampling and biochemical monitoring system for a microbial or cell culture or a biochemical reaction in a bioreactor.

Abstract: A metallic porous membrane that classifies cell aggregates includes a membrane section having a first principal surface for capturing the cell aggregates, a second principal surface opposing the first principal surface, and a plurality of through-holes communicating with the first principal surface and the second principal surface.

Abstract: A closed and modular fluidic system composed of one or more acoustic elements and cell processing reagents. The system employs a cellular manufacturing process for producing cell and gene therapy therapeutics.

Abstract: Disclosed are new uses of lactic acid bacteria, in particular Lactobacillus plantarum, for protecting animals from pathogenic bacterial infection, specifically, methods for reducing the mortality rate of animals against infection of pathogenic bacteria, methods for reducing the growth of pathogenic bacteria in the gastrointestinal tract of the animals, as well as methods of increasing and/or stimulating immune system of the animal through the use of such lactic acid bacteria.

Abstract: Provided is a serum-free culture medium, the ingredients of the culture medium comprising 0.05-0.2 parts by volume of ?-mercaptoethanol, 0.5-2 parts by volume of non-essential amino acid aqueous solution, 4-6 parts by volume of human mesenchymal stem cell culture supernatant concentrate, and 90-95 parts by volume of a-MEM/DMEM-F12 and recombinant human alkaline fibroblast growth factor of a final concentration of 5-5 ng/ml. The present culture medium is used for carrying out stem cell culture.

Abstract: There is provided an improved extraction process for obtaining integral & active thylakoid membranes that have longer shelf-life at room temperature. Particularly, the extract is lyophilized in a solution of PVP and remains stable with at least 80% of its original activity for at least 7 days at room temperature, respectively.

Abstract: The object of the present invention is to provide a method for producing a cell population comprising mesenchymal stem cells having a high specific growth rate which are useful for promptly producing large amounts of cell formulations. The present invention provides a method for producing a cell population comprising mesenchymal stem cells, comprising: a step of treating a cell population comprising mesenchymal stem cells having different proliferative ability by physical stimulation or chemical stimulation, so as to select mesenchymal stem cells having relatively high proliferative ability, wherein the selected mesenchymal stem cells having relatively high proliferative ability are negative for CD106, and the expression level of a metallothionein family gene is increased in comparison to the expression level thereof in the cell population before the treatment by the physical stimulation or chemical stimulation.

Abstract: Provided is a method for rapidly separating and extracting human umbilical cord mesenchymal stem cells (hUC-MSC). The method comprises the following steps: taking freshly collected healthy neonatal umbilical cord tissue, and after removing the blood vessels, bluntly dissecting the Wharton's jelly, mechanically pulverising same, and treating with erythrocyte lysate for 3 minutes; carrying out type IV collagenase digestion, and after sieving through a 100-200 mesh sieve, carrying out suspension culture in a serum-free culture medium, replacing the liquid every 3-5 days; taking the supernatant to detect cell contamination, and waiting for the adherence rate to reach 30-70%; carrying out trypsin digestion, collecting the cells by centrifugation, and carrying out passage amplification, until the rate of confluence of the cells reaches over 90%; collecting the cells for cryopreservation, and detecting the biological characteristics of the hUC-MSC.

Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.

Abstract: The invention provides a differentiation protocol to generate retinal pigmented epithelial cells (RPECs) for the in vitro differentiation of mammalian pluripotent stem cells to mature, functional retinal pigment epithelial cells (RPEC). A culture system is described that uses defined medium comprising xeno-free optimal combinations of small molecule agonists and antagonists where: (a) pluripotent stem cells are cultured in the absence of feeder cells, serum, or conditioned medium; (b) defined culture conditions is used to obtain an eye-field cell (EFC) population; (c) whereby EFC are subsequently differentiated to RPEC when exposed to culture medium containing small molecule agonists thus producing highly homogenous RPEC; and (d) cultured under optimal conditions until maturation, through stimulation via activin-like signalling through addition of either cyclic AMP or cyclic AMP inducers to produce complete monolayer formation within 21+7 days.

Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.

Abstract: Induced pluripotent stem cells (iPSCs) derived from a T cell of a T cell subset. T cells derived from iPSCs derived from a T cell. Methods of deriving iPSCs from a T cell. Methods of deriving T cells from iPSCs including deriving a T cell of a T cell subset from an iPSC. Methods of engineering chimeric antigen receptor (CAR)-expressing or T cell receptor (TCR)-expressing iPSC. Methods of administering T cells derived using the methods disclosed. Induced pluripotent stem cell lines derived from T cells, methods of deriving induced pluripotent stem cell lines, and methods of deriving T cells from induced pluripotent stem cell lines.

Abstract: The invention relates to a new method for in vitro expansion of CD4+CD25HighCD127?/LOWfoxP3+Tregs, wherein the process of Treg expansion takes place permanently or temporarily at a temperature below 37° C., optimally at a temperature of 33° C., the isolated Tregs are expanded in SCGM or X-vivo-20 medium supplemented with human serum or with foetal bovine serum, and magnetic beads coated with anti-CD3 and anti-CD28 antibodies at 1:1 (cell:bead) ratio and interleukin-2 are added to the culture.

Abstract: Disclosed are a method for preparing induced pluripotent stem cells from endocardium-derived adult stem cells isolated from peripheral blood and a method for differentiating induced pluripotent stem cells into cardiovascular cells. The endocardium-derived adult stem cells are primary culture cells for preparing induced pluripotent stem cells, can be readily isolated and cultured only with a small amount of peripheral blood, have a high proliferation property so as to be storable without generic variation, and can rapidly ensure a cell number so as to be usable in cell therapy. The endocardium-derived adult stem cells have sternness, thereby having high preparation efficiency, and are derived from the endocardium so as to have the epigenetic memory of cardiovascular cells, thereby having an advantage of being able to be differentiated, after preparing induced pluripotent stem cells, into cardiovascular cells such as endothelial cells, smooth muscle cells and cardiomyocytes with a high efficiency.

Abstract: The present disclosure describes methods of differentiating cardiomyocyte progenitor cells and mature cardiomyocyte cells from pluripotent stem cells. The methods may include differentiating pluripotent stems cells on a substrate including (i) laminin-511 or 521 and (ii) laminin-221. The cardiomyocyte progenitor cells and mature cardiomyocyte cells produced by the methods may form a human heart muscle cell line for use in regenerative cardiology. Also described are methods of identifying functional cardiomyocyte progenitor cells and their use in therapeutic applications.

Abstract: The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.

Abstract: A serum-free culture method for human umbilical cord mesenchymal stem cells (hUC-MSC), said method using a step-by-step method to culture hUC-MSC: first using a TME culture medium for culturing for 3-4 hours to promote hUC-MSC adherence, and then switching to a TMD culture medium for rapid amplification.

Abstract: The present invention produces a large number of mesenchymal stem cells in a short time in a medium containing no heterologous components by including a step for culturing a cell population containing mesenchymal stem cells in the presence of a fibronectin fragment.

Abstract: Provided is a method for efficiently and stably separating cells having a high biological activity from a biological tissue, by using a degrading-enzyme composition, which is prepared by adding an enzyme for degrading a major protein of the biological tissue in an amount determined depending on the composition of the major protein to a predetermined amount of a neutral protease and/or a protease derived from Clostridium sp. According to this method, the type and amount of protein-degrading enzyme to be used for isolating cells can be determined from the composition of a major protein of the biological tissue. Thus, cells having a high biological activity can be efficiently separated while reducing the amount of protein-degrading enzyme to be used.

Abstract: The invention relates to the field of pharmacology, specifically the field of drug-drug interactions and nephrotoxicity. An engineered, stable cell line of human renal cells is provided that allows screening for drug-drug interactions and nephrotoxicity.

Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.

Abstract: Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.

Abstract: Use of a catalyst in a method of reducing a substrate, the method comprising contacting a substrate with a catalyst, optionally in the presence of a co-substrate, thereby to generate a reduced substrate. The catalyst is a polypeptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 7. In some methods, the substrate concentration is at least 50 mM.

Abstract: Use of a catalyst in a method of reducing a substrate, the method comprising contacting a substrate with a catalyst, optionally in the presence of a co-substrate, thereby to generate a reduced substrate. The catalyst is a polypeptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 1, SEQ ID NO: 7 or SEQ ID NO: 9. In the method the substrate concentration is at least 50 mM.

Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.

Abstract: Compositions comprising modified recombinant polymerizing enzymes are provided, along with nucleic acid molecules encoding the modified polymerizing enzymes. In some aspects, methods of using such polymerizing enzymes to synthesize a nucleic acid molecule or to sequence a nucleic acid template are provided.

Abstract: Provided is a mutant of the wild type phosphatidylcholine-specific phospholipase C of Bacillus cereus. The mutations involved comprise the amino acid residue at position 63 being mutated from asparagine to aspartic acid, the amino acid residue at position 131 being mutated from asparagine to serine, and the amino acid residue at position 134 being mutated from asparagine to aspartic acid, and may comprise the amino acid residue at position 56 being mutated from tyrosine to alanine, lysine, asparagine, glutamine, histidine or tryptophan, and further, may also comprise the amino acid residue at position 106 being mutated from methionine to valine. Also provided are a polynucleotide molecule encoding the mutant, a nucleic acid construct and a host cell comprising the polynucleotide molecule, a composition comprising the mutant, and the use of the mutant, the polynucleotide molecule, the nucleic acid construct and the host cell.

Abstract: Provided herein are systems, methods, and compositions for the modification of target DNA sequences. More particularly, systems, methods, and compositions for cleaving a target DNA in eukaryotic cells with a guide RNA capable of hybridizing with a target sequence and an RNA-guided DNA nuclease are provided. Also provided are vectors and vector systems which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods for identifying and validating novel CRISPR systems.

Abstract: Described herein are conditional guide RNAs that change their activity status depending on the presence or absence of an input target, forming a complex with an RNA-guided effector and conditionally performing a downstream function on a target nucleic acid. Methods for conditionally performing a downstream function on the target nucleic acid using conditional guide RNAs are also described.

Abstract: The application relates to a polypeptide having beta-glucosidase activity, its method of production and its uses.

Abstract: Disclosed herein are cellulase variants, or active fragments thereof, and polynucleotides encoding same, wherein the cellulase variants, or active fragments thereof, hav endoglucanase activity. Also disclosed herein are compositions comprising said cellulase variants, or active fragments thereof; vectors and/or host cells comprising the polynucleotides encoding said cellulase variants, or active fragments thereof; and methods for making and/or using said cellulase variants, or active fragments thereof and/or compositions containing same; wherein said cellulase variants, or active fragments thereof, have endoglucanase activity.

Abstract: In one embodiment, the invention provides a method of purifying recombinant alpha-galactosidase A. The method includes obtaining a lysate from cells recombinantly expressing alpha-galactosidase A grown in a cell culture medium having non-precipitating phosphate; contacting said lysate with a first chromatography media that binds ?-D-mannopyranosyl or ?-D-glucopyranosyl; eluting alpha-galactosidase A from the first chromatography media to generate a first eluate having alpha-galactosidase A, wherein said eluting includes at least one elution pause between 4 and 16 hours; contacting the first eluate with a second chromatography media that binds galactose binding proteins; and eluting alpha-galactosidase A from said second chromatography media to generate a second eluate containing said recombinant alpha-galactosidase A.

Abstract: Provided is a technique for enabling a liquid of microbial cells having an enzymatic activity to be easily stored and used. The technique is a method for killing a microorganism while maintaining the enzyme titer of a microbial cell liquid, characterized by including adjusting the pH of a liquid of microbial cells having an enzymatic activity, and then performing a heating treatment of the liquid, and also the technique is a method for killing a microorganism while maintaining the enzyme titer of a microbial cell liquid, characterized by including adding a carbohydrate to a liquid of microbial cells having an enzymatic activity, and then performing a heating treatment of the liquid.